Oncology Company's Retrospective Ovarian Cancer Study Yields Compelling Results
Oncology Company's Retrospective Ovarian Cancer Study Yields Compelling Results
Predictive Oncology's Foray into Biomarker Discovery.
Disclaimer: The information presented in this article is based on publicly available information and should not be considered as investment advice or an endorsement of any kind. Readers are encouraged to conduct their own research and consult with a qualified professional before making any investment decisions.
Real-time information is available daily at https://stockregion.net
Predictive Oncology Inc. (NASDAQ: POAI), recognized for its advancements in AI-driven drug discovery and biologics, has recently announced its strategic entry into the biomarker discovery market. This expansion leverages the company's AI/ML-driven platform, which has shown promise in predicting patient outcomes and drug responses in oncology. The move follows compelling results from a retrospective ovarian cancer study conducted with UPMC Magee-Womens Hospital.
Background and Recent Developments
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was the stage for Predictive Oncology to present the results of their ovarian cancer study. In this study, multi-omic machine learning models were utilized to identify key features that could more accurately forecast short-term (two-year) and long-term (five-year) survival outcomes in ovarian cancer patients, surpassing the predictions made using clinical data alone. The success of this study paves the way for further exploration both independently and in collaboration with biopharmaceutical companies.
Dr. Arlette H. Uihlein, MD, SVP of Translational Medicine and Drug Discovery and Medical Director at Predictive Oncology, highlighted the prowess of their active machine learning platform. According to Dr. Uihlein, the platform can selectively utilize diverse patient samples preserved in the company's biobank to predict drug responses with high accuracy. The next step involves applying state-of-the-art deep learning techniques for biomarker discovery related to overall survival (OS) and drug response, achievable with existing resources. This application of deep learning to specific patient cohorts accelerates the initial stages of biomarker discovery, showcasing the platform's versatility.
Raymond Vennare, Chief Executive Officer of Predictive Oncology, emphasized the opportunities presented by the identification of novel cancer biomarkers. He noted that their platform's ability to leverage diversified patient samples and data holds substantial value. Furthermore, the technology's broad applicability includes the development of clinical decision support tools for screening clinical trial enrollment and informing subsequent drug discovery and development.
Vennare also pointed out that these capabilities extend beyond ovarian cancer. The platform can potentially be used in discovering biomarkers for other types of cancer. The company is eager to validate these capabilities through collaborations with leading biopharmaceutical partners and healthcare networks.
Market Potential and Future Prospects
The global biomarker discovery market is expected to reach an estimated $51.5 billion in 2024, according to third-party research.
The company recently released a comprehensive white paper detailing their biomarker discovery capabilities. This document elaborates on Predictive Oncology's innovative use of artificial intelligence and machine learning to expedite early biomarker and drug discovery processes, ultimately benefiting cancer patients worldwide. Their AI platform, known as PEDAL, has been scientifically validated to predict with 92% accuracy whether a tumor sample will respond to a specific drug compound. This high level of accuracy allows for more informed selection of drug/tumor type combinations for subsequent in-vitro testing, potentially reducing the time and cost associated with drug development.
Predictive Oncology's entry into the biomarker discovery market signifies a pivotal advancement in the application of AI and machine learning in oncology. By leveraging their robust AI/ML platform, the company aims to enhance the prediction of patient outcomes and drug responses, thereby contributing to the development of personalized cancer treatments. As they continue to validate their platform's capabilities through collaborations and independent research, Predictive Oncology stands at the forefront of innovation in the biomarker discovery landscape.
Disclaimer: The information presented in this article is based on publicly available information and should not be considered as investment advice or an endorsement of any kind. Readers are encouraged to conduct their own research and consult with a qualified professional before making any investment decisions.
Real-time information is available daily at https://stockregion.net